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The events that occur after the binding of the enzymatic E colicins to Escherichia coli BtuB receptors that
lead to translocation of the cytotoxic domain into the periplasmic space and, ultimately, cell killing are poorly
understood. It has been suggested that unfolding of the coiled-coil BtuB receptor binding domain of the E
colicins may be an essential step that leads to the loss of immunity protein from the colicin and immunity
protein complex and then triggers the events of translocation. We introduced pairs of cysteine mutations into
the receptor binding domain of colicin E9 (ColE9) that resulted in the formation of a disulfide bond located
near the middle or the top of the R domain. After dithiothreitol reduction, the ColE9 protein with the mutations
L359C and F412C (ColE9 L359C-F412C) and the ColE9 protein with the mutations Y324C and L447C (ColE9
Y324C-L447C) were slightly less active than equivalent concentrations of ColE9. On oxidation with diamide,
no significant biological activity was seen with the ColE9 L359C-F412C and the ColE9 Y324C-L447C mutant
proteins; however diamide had no effect on the activity of ColE9. The presence of a disulfide bond was
confirmed in both of the oxidized, mutant proteins by matrix-assisted laser desorption ionization–time of flight
mass spectrometry. The loss of biological activity of the disulfide-containing mutant proteins was not due to
an indirect effect on the properties of the translocation or DNase domains of the mutant colicins. The data are
consistent with a requirement for the flexibility of the coiled-coil R domain after binding to BtuB.
Colicins are plasmid-encoded antibacterial proteins that are
secreted as part of the stress response system of Escherichia
coli to kill other bacteria. They are classified into types on the
basis of the cell surface receptor on the target cells to which
they bind. All E colicins bind to the product of the chromo-
somal btuB gene, an outer membrane protein which is an
essential component of the high-affinity transport system for
vitamin B12 in E. coli, and require the outer membrane protein
OmpF as a coreceptor (19). Based on immunity tests (9, 38)
the E colicins have been subdivided into nine subtypes, colicin
E1 (ColE1) to ColE9. These fall into one of three cytotoxic
classes: membrane-depolarizing or pore-forming agents such
as ColE1 (10); DNases such as ColE2, ColE7, ColE8, and
ColE9 (9); and RNases such as ColE3, ColE4, ColE5, and
ColE6 (25, 28). In common with most colicins, the enzymatic
E-type colicins consist of three functional domains. The killing
activity is contained in the C-terminal domain, which can be
isolated as a stable and active protein (15, 21, 29, 37). The
central section contains the receptor-binding (R) domain,
while the N-terminal T domain is responsible for translocation
of the cytotoxic domain into the cytoplasm of the target cell (1,
14). After binding to their outer membrane receptors, group A
colicins, such as ColE9, are translocated across the membrane
in a process which is mediated by the tol system (23). Trans-
location requires a specific pentapeptide sequence in the T
domain, known initially as the TolA box (31), but which is now
known to interact with TolB (4, 7). ColE9 contains a TolB box
from residues 35 to 39, DGSGW, which has been shown by
mutagenesis to be important for its killing action (14) and for
the interaction of the T domain with the translocation protein
TolB (7). The mechanism by which TolB recognizes and spe-
cifically binds to the TolB box sequence is unknown; however,
recent nuclear magnetic resonance (NMR) experiments have
shown that the T domain of ColE9 contains a large structurally
disordered region that possesses a high degree of flexibility (8).
The recent X-ray structure of the RNase ColE3 (35) did not
reveal any resolved electron density for residues 1 to 83, a
region of the T domain whose sequence is highly conserved in
the enzymatic E colicins and, thus, might be expected to be
similarly flexible.
The mechanism by which the cytotoxic C-terminal domains
of enzymatic E colicins are translocated to the cytoplasm of
E. coli cells, across the outer membrane, the periplasmic space,
and the cytoplasmic membrane is an impressive feat and is
probably unique in bacteria. The events that take place after
receptor binding are speculative but presumably require the
entry of at least part of the T domain of a tol-dependent colicin
into the periplasm of the target E. coli cell, where it can
interact with Tol proteins such as TolB (6), and in some way
open a pathway in the outer membrane that allows entry of the
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cytotoxic domain. Information on the mechanism by which the
enzymatic domain reaches the cytoplasm is very limited; how-
ever, it was recently reported that the DNase domains of
ColE9 and ColE2 exhibit channel-forming activity in planar
lipid bilayers that is linked to toxin translocation across the
cytoplasmic membrane of E. coli cells (27).
Here we report that the introduction of cysteine residues in
the R domain of ColE9, in positions where a disulfide bond can
be formed, inhibits colicin activity without significantly affect-
ing BtuB binding, or binding to TolB. The addition of dithio-
threitol (DTT) to the oxidized proteins containing disulfide
bonds restored colicin activity. These observations are consis-
tent with a requirement for a conformational change in the R
domain that is essential for colicin activity.
MATERIALS AND METHODS
Plasmids, bacterial strains, and media. E. coli JM83 (ara [lac-proAB] rpsL
80lacZM15) was used as the host strain for cloning and mutagenesis. E. coli
BL21(DE3) or ER2566 (Novagen) was used as the host strain for the expression
vector pET21a (Novagen), which has a strong, IPTG (isopropyl--D-thiogalac-
topyranoside)-inducible T7 polymerase promoter and a C-terminal polyhistidine
tag (His-tag) to facilitate the purification of overexpressed proteins as ColE9/Im9
complexes. E. coli DH5 (Invitrogen) was used as a colicin-sensitive strain to
determine growth inhibition by ColE9 and mutant proteins. E. coli 113/3 is a
metE mutant of the W strain of E. coli (ATCC 9637) (11). All cultures were
routinely grown in Luria-Bertani (LB) broth, or on plates of LB agar, supple-
mented where required with ampicillin (100 g ml1). Plasmid pCS4, that
encodes the ceaI gene, together with the ceiI immunity gene with a C-terminal
His-tag, under the control of an inducible T7 promoter has been previously
described (15) and was used as the template DNA to introduce cysteine muta-
tions into the ceaI gene.
Site-directed mutagenesis. Site-directed mutants of the R domain of ColE9
were constructed by using the megaprimer PCR method (34). A mutagenic
primer was used in conjunction with a suitable forward or reverse primer to
obtain a PCR product, which was then used as a megaprimer in a second-stage
PCR. The final PCR product containing the desired mutation in the ceai gene
was isolated by using the QIAEX-II gel extraction kit (QIAGEN) and cloned
into the required plasmid vector.
Colicin activity assays. Colicin titers were determined by spotting 2-l samples
of purified ColE9/Im9 protein complex (serially diluted in 50 mM K2HPO4 
KH2PO4 buffer [pH 7.0]; 0.1 mg of bovine serum albumin ml1) onto a large,
square LB agar plate containing ampicillin (100 g ml1) that was overlaid with
a soft agar lawn of the sensitive indicator strain E. coli DH5 (pUC18) (36). The
colicin titer is the lowest concentration of colicin complex that produces a clear
zone of inhibition in the indicator lawn.
Protein purification. pET vectors (Novagen) encoding ColE9 mutant proteins
along with a polyhistidine-tagged Im9 were transformed into E. coli ER2566 or
BL21(DE3) cells. ColE9/Im9 complexes were purified as previously described by
metal chelate chromatography (14) with an elution buffer containing 1 M imi-
dazole, 0.5 M NaCl, and 20 mM Tris-HCl (pH 7.9). Protein concentrations were
determined by absorbance at 280 nm.
Diamide oxidation and DTT reduction. ColE9 mutant protein complexes were
dialysed overnight against reducing buffer (50 mM K2HPO4  KH2PO4 buffer
[pH 7.0], 1 mM DTT), with up to four 5-ml fractions in 5 liters of buffer. For
diamide oxidation, the protein samples were dialysed overnight against 50 mM
K2HPO4  KH2PO4 buffer, pH 7.0, to remove the DTT. Protein samples were
then adjusted to 1 mM with diamide and incubated for 30 min in the dark at
room temperature, before overnight dialysis against nonreducing buffer (50 mM
K2HPO4  KH2PO4 buffer, pH 7.0).
MALDI-TOF mass spectrometry. Tryptic digests were carried out in 25 mM
ammonium bicarbonate buffer, pH 8.5. A total of 2 g of each ColE9/Im9
complex was incubated with 80 ng of trypsin at room temperature for 5 h before
the addition of 60 ng of trypsin inhibitor to stop the reaction. Trypsin-digested
ColE9/Im9 protein complexes were divided into 15-l aliquots, one of which was
reduced by the addition of DTT to a final concentration of 1 mM; the other was
left in its oxidized form. A total of 2 l of each sample was spotted onto a 96-well
matrix-assisted laser desorption ionization (MALDI) plate, each spot being over-
laid with 1 l of alpha-cyano 4-hydroxy cinnamic acid (10 mg ml1) in 50%
acetonitrile, 0.1% trifluoroacetic acid. MALDI-time of flight (TOF) experiments
were carried out by using an Applied Biosystems 4700 proteomics analyzer.
Differences between the spectra of the oxidized and the reduced digested pro-
teins were analyzed to detect peaks in the oxidized spectra corresponding to two
cysteine-containing peptides linked through a disulfide bond.
BtuB binding assays. We used two different assays of BtuB receptor binding
that have both been previously described (30). The biological protection assay
determines the ability of ColE9 mutant protein complexes to protect E. coli cells
from killing by ColE9/Im9 and was performed as previously described (30) but by
using E. coli DH5 cells. In the vitamin B12 competition assay, E. coli 113/3 was
grown overnight in L broth at 37°C with aeration. The cells were diluted 1:100 in
50 ml of M9 minimal medium supplemented with 0.2% (wt/vol) glucose, 10 mM
MgSO4, 20 mM CaCl2, 100 g of thiamine ml1, 1 nM vitamin B12, and various
concentrations of ColE9 mutant protein complexes. The cells were grown for
approximately 6 h, and measurements of growth were taken at 30-min intervals
by determining the optical density at 600 nm.
Nuclease activity. Duplicate Kunitz assays were performed as described pre-
viously (33). Briefly, assays were carried out in volumes of 1 ml containing 50 mM
Tris-HCl (pH 7.5), 20 mM MgS04, and 50 g of calf thymus DNA at a temper-
ature of 25°C. For these assays, only ColE9 and ColE9 mutant proteins were
purified in the absence of Im9 under denaturing conditions by using 6 M gua-
nidine hydrochloride as previously described (14). The reaction was initiated by
the addition of 50 g of ColE9, and DNA hydrolysis was monitored at 2-min
intervals by the change in hyperchromicity at 260 nm by using a Philips PU 8730
spectrophotometer.
Surface plasmon resonance. The interaction of the complex of the oxidized
ColE9 protein with mutations L359C and F412C (L359C-F412C)/Im9 and of the
complex of ColE9 with mutations Y324C and L447C (Y324C-L447C)/Im9 with
TolB was compared to the interaction with ColE9/Im9 by using surface plasmon
resonance (SPR) (20). TolB (50 g/ml) was coupled to a CM5 sensor chip by
using an amine-coupling kit (Biacore AB, Uppsala, Sweden) with a 6-min contact
time. After deactivation, the relative response between charged and uncharged
flow cells was 5,000. ColE9/Im9 complex (3 M) diluted in HBS buffer (0.01 M
HEPES [pH 7.4], 0.15 M NaCl, 3 mM EDTA, 0.005% [vol/vol] surfactant P20),
pH 7.4, was injected over a TolB chip for 2 min, followed by a 10 mM glycine
regeneration. The same experiment was then repeated with oxidized ColE9
L359C-F412C/Im9 and ColE9 Y324C-L447C/Im9 mutant proteins. The experi-
ment was repeated three times with very similar results on each occasion.
CD. Circular dichroism (CD) spectra were measured on a JASCO J-810
spectropolarimeter, thermostated at 22°C. All protein samples were prepared at
a concentration of 3.5 M in 10 mM potassium phosphate buffer, pH 7.0. Data
were collected between 190 and 250 nm in a 1-mm path length. All spectra were
corrected for buffer contributions.
RESULTS
Introducing disulfide locks in the R domain. The minimum
R domain of ColE9, as shown by deletion subcloning and assay
of the ability of the resulting purified proteins to bind to BtuB,
consists of residues 343 to 418 (30). A recent paper reporting
the three-dimensional structure of ColB (18) questioned the
location of the R domain of ColE9 (30). This suggestion ig-
nores the overwhelming evidence that supports the identifica-
tion of the R domain: (i) the three-dimensional structure of the
complex of BtuB and the 135 residues of the coiled-coil R
domain (R135) shows the molecular details of the interaction
(22); (ii) the demonstration that a 34-residue peptide, located
within the R domain, binds to BtuB with nanomolar affinity
(26); and (iii) the demonstration that the 76-residue R domain
peptide competes for binding with vitamin B12 (30).
Because of the 100% sequence conservation between the
TR domains of ColE9 and ColE3, we can assume that the
structure of these two domains in ColE9 will be identical to
that recently reported for ColE3 (35). This is supported by
solution NMR data for the 76-residue R domain, which indi-
cate a helical structure in a rod-like, elongated shape (2). The
R domain of ColE3 is a 100-A˚ long antiparallel alacoil of the
ROP type with a seven-residue hairpin linking the two arms of
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the coiled-coil (35). The 76-residue R domain constitutes ap-
proximately the bottom half of the alacoil including the hair-
pin. In order to investigate the role of conformational changes
of the R domain in colicin killing, we introduced cysteine
mutations in the helices of the R domain of ColE9 in order to
create a disulfide bond that would “lock” the conformation of
the R domain. Engineered disulfide bonds have been shown to
be a useful tool to probe the structural events that accompany
the translocation of toxins across membranes (13, 27). We
identified two pairs of candidate residues to mutate to cys-
teines, L359C-F412C and Y324C-L447C (Fig. 1). The L359C-
F412C cysteines are estimated to be 1.6 A˚ apart and were
chosen as they are located near the middle of the coiled-coil R
domain, while the Y324C-L447C cysteines are estimated to be
1.83 A˚ apart and are located near the top of the coiled-coil.
We reasoned that there might be differences in properties
between mutant colicins containing a disulfide bond located
near the top of the R domain, where the effect of unfolding
might be more significant than that occurring near the middle
of the coiled-coil.
We made single cysteine mutations at the four positions and
confirmed that there was no effect on the titers of the purified
ColE9 mutant protein/Im9 complexes compared to titers of the
ColE9/Im9 complex. The double mutants were constructed,
and the resulting plasmid constructs were sequenced to con-
firm the presence of both cysteine mutations in the R domain.
Plasmid pBHZ2 encodes ColE9 containing the L359C-F412C
mutations, while plasmid pBH29 encodes ColE9 containing
the Y324C-L447C mutations. The mutant ColE9 proteins
encoded by pBHZ2 and pBH29 (which were called ColE9
L359C-F412C and ColE9 Y324C-L447C, respectively) were
then overexpressed as a complex with Im9 and purified by
making use of the polyhistidine tag at the C terminus of the
Im9 immunity gene as previously described (14). As a control,
we constructed plasmid pBH16 which encodes ColE9 contain-
ing the mutations Y324C and V405C (Y324C-V405C), posi-
tions in which the cysteines should be too far apart to form a
disulfide bond. The ColE9 Y324C-V405C/Im9 mutant protein
was then purified as a polyhistidine-tagged complex from cells
containing plasmid pBH16.
Each of the three purified protein preparations was split into
two samples, one of which was oxidized with diamide, and the
other was reduced with DTT. The activity of the two samples
of each mutant protein was then compared with that of the
ColE9/Im9 complex in the large plate assay of biological ac-
tivity (Fig. 2). After DTT reduction, all three of the mutant
proteins were 8- to 16-fold less active than equivalent concen-
trations of ColE9/Im9. A similar result has been observed with
the introduction of two cysteine residues into the DNase do-
main of ColE9 (27). After oxidation with diamide, no zones of
inhibition were visible with ColE9 L359C-F412C/Im9, while
oxidized ColE9 Y324C-L447C/Im9 produced very faint zones
of inhibition. The activity of ColE9 Y324C-V405C/Im9 was
identical in the oxidized or reduced samples.
In a liquid growth inhibition experiment, we added ColE9
L359C-F412C/Im9 or ColE9 Y324C-L447C/Im9 mutant pro-
teins that had either been oxidized or reduced to growing E.
coli DH5 cells (Fig. 3A). The chosen 30 nM concentration of
the mutant proteins was extrapolated from the concentration
values required to kill E. coli DH5 cells shown in Fig. 2. The
results confirmed the plate assay data that oxidized ColE9
L359C-F412C/Im9 or ColE9 Y324C-L447C/Im9 mutant pro-
teins, unlike the DTT-reduced mutant proteins, had no inhib-
itory activity. There was a reproducible difference in the rela-
tive killing activity in this liquid growth assay, with the ColE9
Y324C-L447C/Im9 mutant protein showing less killing activity
than the ColE9 L359C-F412C/Im9 mutant protein. In contrast,
the ColE9 Y324C-V405C/Im9 mutant protein, whether oxi-
dized or reduced, exhibited similar growth inhibition to 3 nM
ColE9/Im9 (data not shown). The simultaneous addition of
DTT and oxidized ColE9 L359C-F412C/Im9 or ColE9 Y324C-
L447C/Im9 mutant proteins to E. coli DH5 cells resulted in
the timing of growth inhibition (Fig. 3B) that was very similar
to that seen in the results shown in Fig. 3A. This indicates that
DTT reduction of the oxidized mutant proteins in the growth
medium and/or bound to E. coli cells must occur quickly. The
ColE9 L359C-F412C/Im9 mutant protein was less active in the
FIG. 1. Structure of ColE3 (35) with the location of the disulfide
bond formed between the C324-C447 and C359-C412 mutations in the
R domain of ColE9 indicated in spacefill.
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presence of DTT than the ColE9 Y324C-L447C/Im9 mutant
protein.
The properties of the ColE9 L359C-F412C/Im9 and ColE9
Y324C-L447C/Im9 mutant proteins were consistent with a di-
sulfide being formed between the two introduced cysteine res-
idues in the R domain. We directly confirmed the presence of
a disulfide bond in tryptic digests of the oxidized but not the
reduced ColE9 L359C-F412C/Im9 (Fig. 4) and ColE9 Y324C-
FIG. 2. Growth inhibitory activity of disulfide lock mutant proteins. The growth inhibitory activity of the ColE9 L359C-F412C, ColE9
Y324C-L447C, and ColE9 Y324C-V405C mutant proteins is shown compared to ColE9 in a large-plate assay. Aliquots of doubling dilutions of
each of the proteins, containing concentrations of between 0.6 nM and 1.2 M, were spotted onto a large agar plate spread with the indicator E. coli
DH5. A clear zone in the lawn of cells indicates growth inhibition by the colicin protein at that dilution.
FIG. 3. Growth inhibitory activity in liquid medium. (A) The effect on E. coli DH5 cells grown in LB medium, with no additions (E), with
3 nM ColE9 (F), with 30 nM oxidized ColE9 Y324C-L447C mutant protein (), with 30 nM reduced ColE9 Y324C-L447C mutant protein (), with
30 nM oxidized ColE9 L359C-F412C mutant protein (‚), or with 30 nM reduced ColE9 L359C-F412C mutant protein (Œ). (B) The effect on E. coli
DH5 cells grown in LB medium, with no additions (E), with 1 mM DTT (), with 3 nM ColE9 (F), with 30 nM oxidized ColE9 Y324C-L447C mu-
tant protein plus 1 mM DTT (), or with 30 nM oxidized ColE9 L359C-F412C mutant protein plus 1 mM DTT (Œ). OD600, optical density at 600 nm.
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L447C/Im9 (data not shown) mutant proteins by MALDI-TOF
mass spectrometry. The expected mass of the disulfide-linked
peptide whose sequence is shown in Fig. 4 is 2836.4, and the
observed mass of the central peak arising from the oxidized
protein is 2837.4. The series of peaks in the oxidized spectra,
differing in size by 1 Da, arise due to variation in the incorpo-
ration of natural isotopes. With the reduced protein the ex-
pected 1,991-Da peak was observed for the peptide at residues
356 to 374 shown in Fig. 4, and as expected this peak was
significantly reduced in the oxidized protein. The 848-Da peak
corresponding to the peptide at residues 409 to 417 was not
resolved in either spectra.
Receptor-binding, DNase, and TolB binding activity of the
mutant proteins. The simplest explanation for our findings is
that the presence of a disulfide in the R domain prevents a
conformational change that is essential for biological activity.
There are, however, several alternative explanations for the
loss of colicin activity of the oxidized ColE9 L359C-F412C/Im9
and ColE9 Y324C-L447C/Im9 mutant proteins. The presence
of the disulfide lock in the R domain could affect the binding
of the mutant protein to the BtuB receptor in the outer mem-
brane of E. coli cells, the DNase activity of the mutant protein,
or the interaction of the T domain of the mutant protein,
especially the TolB box, with TolB, or result in a significant
structural change of the colicin molecule. We investigated
these possibilities in turn by using a range of experimental
techniques.
FIG. 4. Presence of a disulfide confirmed by MALDI-TOF. The spectra of the oxidized (right) and reduced (left) ColE9 L359C-F412C mutant
protein is shown. The sequence and residue numbers of a disulfide-containing peptide observed in the oxidized ColE9 L359C-F412C protein
spectra are indicated at the top of the figure.
FIG. 5. Assay of BtuB receptor binding. In vivo competition assay
using E. coli DH5 cells incubated with no additions (E), with 3 nM
ColE9 (F), with 300 nM ColE9 L359C-F412C mutant protein (), and
with 3 nM ColE9 and the ColE9 L359C-F412C mutant protein at a
ratio of 1:1 (‚), 1:10 (Œ), or 1:100 (X). OD600, optical density at 600 nm.
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The relative concentration of the oxidized ColE9 Y324C-
L447C/Im9 mutant protein required to protect E. coli DH5
cells from killing by wild-type ColE9 (Fig. 5) was similar to that
previously reported for the active site ColE9 H575A/Im9 mu-
tant protein (14). The oxidized L359C-F412C/Im9 protein also
protected E. coli DH5 cells from killing by wild-type ColE9/
Im9 (data not shown). The oxidized ColE9 L359C-F412C/Im9
or ColE9 Y324C-L447C/Im9 mutant protein inhibited the
growth of E. coli 113/3, a metE mutant that is unable to make
methionine unless supplied with vitamin B12, in a similar way
to that previously reported for the ColE9 H575A/Im9 mutant
protein (data not shown).
We investigated whether the presence of the disulfide bond
affects the DNase activity of the oxidized ColE9 L359C-F412C
or ColE9 Y324C-L447C mutant protein by using a Kunitz
DNase assay after removal of the bound Im9 protein from the
complexes (Fig. 6). As has been reported previously, the in-
crease in absorbance at 260 nm is nonlinear with ColE9 in the
presence of Mg2, although this is the preferred metal ion for
double-stranded DNA cleavage (32, 33). Surprisingly, the
DNase activity both of the oxidized or reduced ColE9 Y324C-
L447C mutant protein and of the oxidized ColE9 L359C-
F412C mutant protein was diminished compared with the
ColE9 control protein. The activity of the reduced ColE9
L359C-F412C mutant protein was very similar to that of the
ColE9 control protein. In the same assay, we also confirmed
that the DNase activity of the oxidized ColE9 L359C-F412C or
ColE9 Y324C-L447C mutant protein, like that of ColE9, is
inhibited by binding Im9 (data not shown).
An interaction between the T domain of ColE3 and TolB
was demonstrated by cross-linking experiments (5). An in-
teraction between the T domain of ColE9 and TolB was
demonstrated by using the yeast two-hybrid system (7). This
interaction was shown by alanine scanning mutagenesis to
be dependent upon any one of the three italicized residues in
the pentapeptide TolB box sequence DGSGW (14). SPR has
been used previously to show an interaction between TolA and
the T domains of ColA (12) or ColN (16). We compared the
interaction between TolB and the ColE9 L359C-F412C/Im9
and ColE9 Y324C-L447C/Im9 mutant protein complexes with
that of ColE9/Im9 by using SPR. The presence of disulfide
locks in the two mutant proteins had no inhibitory effect on the
interaction between their TolB boxes and TolB (data not
shown).
CD provides secondary structure information, allowing the
detection of secondary structure perturbations in a protein
caused by site-directed mutagenesis. The CD spectra of the
oxidized ColE9 L359C-F412C/Im9 and ColE9 Y324C-L447C/
Im9 mutant proteins superimpose with the spectra of the na-
tive ColE9/Im9 protein (data not shown); therefore, neither
the introduction of the pairs of cysteine residues nor the for-
mation of the disulfide bond had any detectable effect on the
global secondary structure of ColE9.
DISCUSSION
Recognition of the cell surface receptor is the first stage in
colicin killing of E. coli cells. The fact that enzymatic colicins
bind to the BtuB receptor has been known for decades, and the
role of the Tol proteins that are required for translocation of
the colicin through the periplasm has received much attention
over the last 20 years (3, 24). But the sequence of events that
occur after receptor binding and the overall dynamics of the
system remain to be elucidated. In this paper we provide evi-
dence that the flexibility of the R domain is essential for the
activity of enzymatic colicins and that the structural rigidity of
the coiled-coil prevents subsequent events from occurring dur-
ing cell entry.
The introduction of two cysteine mutations in the R domain
of ColE9 results in the formation of a disulfide bond in the
diamide-oxidized ColE9 L359C/F412C/Im9 and ColE9 Y324C-
L447C/Im9 mutant proteins that abolishes colicin activity. Re-
duction of the mutant protein by dialysis into DTT-containing
buffer restored colicin activity; this result was also observed in
a liquid growth inhibition experiment by the addition of DTT
to E. coli DH5 cells incubated with the oxidized ColE9
Y324C-L447C/Im9 or ColE9 L359C-F412C/Im9 mutant pro-
teins (Fig. 3B). The differences in growth inhibition of the two
mutant proteins seen in each assay could be due to a difference
in accessibility of the disulfides to DTT reduction and/or spon-
taneous oxidation of the disulfide. The presence of the ex-
pected disulfide bond in tryptic digests of the diamide-oxidized
FIG. 6. DNase activity assays. The DNase activities of the oxidized
(‚) and reduced (Œ) ColE9 L359C-F412C and the oxidized () and
reduced () ColE9 Y324C-L447C mutant proteins were compared to
that of ColE9 (F) by using the Kunitz assay. The Im9 protein was
removed from the ColE9 proteins to allow the DNase assay to be
performed. OD260, optical density at 260 nm.
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ColE9 L359C-F412C or ColE9 Y324C-L447C mutant pro-
tein, but not in the DTT-reduced proteins, was confirmed by
MALDI-TOF mass spectrometry. In contrast to these results,
the control ColE9 Y352C-V405C/Im9 mutant protein exhib-
ited almost identical colicin activity after diamide oxidation or
DTT reduction. The observation of a disulfide bond in the
ColE9 L359C-F412C and ColE9 Y324C-L447C mutant pro-
teins is consistent with the predicted distance between the pairs
of cysteine residues when modeled on the three-dimensional
structure of ColE3 (35) (Fig. 1).
The loss of biological activity of the oxidized ColE9 L359C-
F412C/Im9 or ColE9 Y324C-L447C/Im9 mutant protein com-
plex was not due to a significant effect of the disulfide bond
present in the protein on BtuB binding, as the diamide-treated
proteins both protected E. coli cells from killing by ColE9/Im9
in similar ratios to those seen previously for the inactive ColE9
H575A/Im9 mutant colicin in a protection experiment (Fig. 5)
and also competed for BtuB binding with vitamin B12. The
presence of a disulfide bond in the ColE9 L359C-F412C/Im9
or ColE9 Y324C-L447C/Im9 mutant protein had no inhibitory
effect on the TolB binding activity of the mutant proteins or on
the CD spectrum of the oxidized proteins, but it did have some
effect on their DNase activity (Fig. 6). The DNase assay ex-
periments require denaturation of the ColE9 mutant protein in
order to remove the bound Im9 protein from the complex,
followed by refolding. It is possible that the presence of a
disulfide might interfere differently with the refolding process
in the two mutant proteins.
Our data clearly show that locking the conformation of the
R domain by the presence of a disulfide, located either near
the middle or at the top of the coiled-coil, abolishes the bio-
logical activity of the mutant colicin. This provides support for
a model of ColE9-induced cell killing in which the flexibility of
the coiled-coil R domain is essential for the events that occur
after BtuB receptor binding. Several authors have previously
suggested that the unfolding of the R domain is essential for
colicin activity (17, 35), but there is little direct experimental
evidence to support the hypothesis. An analysis of ColE1 by
differential scanning calorimetry and CD suggested that the R
domain has a dominant role in determining the conformation
of the other two domains (17). Although the crystal structure
of ColE1 does not include the R and T domains, it was pro-
posed that the unfolding of the R domain coiled-coil after
binding to BtuB results in unfolding of the T domain, which
then interacts with TolC and initiates the translocation pro-
cess.
Recently the three-dimensional structure of BtuB bound to
R135 of ColE3 was determined (22). The perhaps surprising
observation from this structure is that the coiled-coil R domain
is not buried in a binding pocket in BtuB. The three-dimen-
sional structure shows that 27 residues of R135 (from I369 to
T402), located around and including the hairpin, interact with
29 residues of BtuB. Most of the BtuB residues that interact
with R135 are located in the exposed loops, but four residues
of the N-terminal plug domain of BtuB interact with M383
located in the hairpin of R135. The buried surface area of
R135 bound to BtuB is 1,533 A˚2, which constitutes 24% of the
coiled-coil domain of ColE3. The location of both of the di-
sulfide locks in the coiled-coil domain is outside the region that
interacts with BtuB, which explains why the receptor binding of
our constructs was not affected.
By using far-UV CD to measure the helical content of R135,
it was demonstrated that the helical content decreased by 12%
	 5% on BtuB binding (22). By comparing the C displace-
ment of the residues in the bound R135 domain with that of
ColE3, disorder of the coiled-coil was observed in the crystal
structure of the R domain BtuB complex (22). The C dis-
placement increased with the distance from the helical hairpin,
with values of 3.5 A˚ and 6 A˚ for Y323 and K438, respectively.
It was suggested that the function of these observed changes in
the conformation of the coiled-coil is to drive the unfolding of
the R domain which, if transmitted to the T domain, could lead
to the dissociation of the T domain from its interface with Im3,
and also the unfolding of the T domain to allow its penetration
into the periplasmic space and interaction with Tol proteins
(22). There remains uncertainty, however, about the magni-
tude of the conformational change since there is no evidence
that the three-dimensional structure of the truncated R135
polypeptide in solution is identical to that of the complete R
domain observed in the X-ray structure of ColE3 (35). A 34-
residue peptide, corresponding to residues 366 to 399 of ColE3
containing two cysteines that were introduced to enable for-
mation of a disulfide cross-link for minimization of conforma-
tional entropy, was shown to bind to BtuB with nanomolar
affinity (26). This BtuB binding peptide, however, also pos-
sessed less secondary structure than the same sequence within
the complete ColE3 protein. Solution NMR studies of the
76-residue minimum R domain have shown that its helical
hairpin structure has multiple, slowly interchanging conform-
ers and a flexible hairpin loop (2). A plausible interpretation of
all these data is that, in solution, the coiled-coil R domain and
truncated versions thereof can adopt a variety of structures
differing in the spatial relationship of the two helices.
Our data support the hypothesis that the unfolding and
flexibility of the R domain are necessary for subsequent trans-
location events. There are a number of unanswered questions
resulting from an unfolding model, such as the magnitude of
the conformational change in the R domain described above
and whether this results in similar changes in the T domain
and/or triggers the loss of immunity protein from the colicin/
immunity protein complex. We are currently developing exper-
imental tools to explore the early events of the translocation
process.
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